The evolutionary history of lethal metastatic prostate cancer
G. Steven Bova(Prostate Cancer Research), Rosalind A. Eeles(Royal Marsden NHS Foundation Trust), Hayley C. Whitaker(University of Cambridge), Gunilla Högnäs(Tampere University), Peter J. Campbell(Wellcome Sanger Institute), Kati Kivinummi(Tampere University), Heini Kallio(Tampere University), Matti Annala(Tampere University), Douglas F. Easton(University of Cambridge), José M. C. Tubío(Wellcome Sanger Institute), Zsofia Kote‐Jarai(Institute of Cancer Research), Bárbara Kremeyer(Wellcome Sanger Institute), Matti Nykter(University of Liverpool), William B. Isaacs(Unknown), Victoria Goody(Wellcome Sanger Institute), Elli Papaemmanuil(Memorial Sloan Kettering Cancer Center), Peter Van Loo(Wellcome Sanger Institute), Ultan McDermott(AstraZeneca (United Kingdom)), Ludmil B. Alexandrov(UC San Diego Health System), Gunes Gundem(Memorial Sloan Kettering Cancer Center), Tapio Visakorpi(Tampere University Hospital), Daniel S. Brewer(University of East Anglia), Calli Latimer(Wellcome Sanger Institute), David E. Neal(University of Cambridge), Christopher S. Foster(Institute of Cancer Research), Colin S. Cooper(University of East Anglia), Kevin J. Dawson(Wellcome Sanger Institute), Michael R. Emmert‐Buck(Rex Medical (United States)), David C. Wedge(University of Manchester), Sarah O’Meara(Wellcome Sanger Institute)
Cited by 1,436
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
COSMIC: the Catalogue Of Somatic Mutations In Cancer
|Nucleic Acids Research|2018|5.2k
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k
The cancer genome
|Nature|2009|3.5k
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
|The Lancet|2005|3.4k